This company has been acquired
AVEO Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Key information
134.1%
Debt to equity ratio
US$38.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$77.40m |
| Equity | US$28.85m |
| Total liabilities | US$72.39m |
| Total assets | US$101.23m |
Recent financial health updates
Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04
Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24AVEO Oncology: Time To Be Patient
Jun 07AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication
Jan 07AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Dec 27Financial Position Analysis
Short Term Liabilities: AVEO's short term assets ($100.7M) exceed its short term liabilities ($42.4M).
Long Term Liabilities: AVEO's short term assets ($100.7M) exceed its long term liabilities ($30.0M).
Debt to Equity History and Analysis
Debt Level: AVEO has more cash than its total debt.
Reducing Debt: AVEO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVEO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AVEO has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 12.7% each year.